Celon Pharma (WAR:CLN) EV-to-EBITDA : 17.62 (As of May. 29, 2025)

Celon Pharma EV-to-EBITDA Chart

Celon Pharma Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBITDA		Get a 7-Day Free Trial				60.16	60.98	48.00	61.99	21.41

Celon Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Mar25
EV-to-EBITDA	Get a 7-Day Free Trial															21.41	17.94	47.72	16.92	21.04

Competitive Comparison of Celon Pharma's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celon Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Celon Pharma's EV-to-EBITDA falls into.

Celon Pharma EV-to-EBITDA Calculation

Celon Pharma's EV-to-EBITDA for today is calculated as:

Celon Pharma's current Enterprise Value is zł1,154.8 Mil.
Celon Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was zł65.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma  (WAR:CLN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Celon Pharma's PE Ratio (TTM) for today is calculated as:

Celon Pharma's share price for today is zł22.05.
Celon Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.440.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Celon Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Celon Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Celon Pharma Business Description